|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Vytorin
gptkb:Zetia
|
|
gptkbp:activities
|
inhibits intestinal absorption of cholesterol
|
|
gptkbp:approves
|
gptkb:2002
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Ezetrol
gptkb:Vytorin
gptkb:Zetia
|
|
gptkbp:can_be_used_with
|
gptkb:simvastatin
gptkb:rosuvastatin
gptkb:atorvastatin
|
|
gptkbp:category
|
gptkb:unknown
not recommended
|
|
gptkbp:class
|
cholesterol absorption inhibitor
|
|
gptkbp:clinical_trial
|
Phase III
approximately 35%
as adjunct to diet
in combination with statins
in patients with familial hypercholesterolemia
in patients with atherosclerotic cardiovascular disease
|
|
gptkbp:contraindication
|
active liver disease
hypersensitivity to ezetimibe
|
|
gptkbp:developed_by
|
gptkb:Schering-Plough
|
|
gptkbp:dosage_form
|
10 mg tablet
|
|
gptkbp:excretion
|
bile
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ezetimibe
|
|
gptkbp:indication
|
hyperlipidemia
|
|
gptkbp:ingredients
|
C24 H21 F2 N3 O3 S
|
|
gptkbp:interacts_with
|
statins
|
|
gptkbp:invention
|
gptkb:2016
|
|
gptkbp:is_atype_of
|
C10 A X09
|
|
gptkbp:is_available_on
|
gptkb:tablet
|
|
gptkbp:is_monitored_by
|
liver function tests
lipid levels
|
|
gptkbp:is_used_for
|
lowering cholesterol
|
|
gptkbp:lifespan
|
22 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Merck_&_Co.
|
|
gptkbp:metabolism
|
glucuronidation
|
|
gptkbp:pharmacokinetics
|
absorbed in the intestine
lowers LDL cholesterol
|
|
gptkbp:population
|
adults
children over 10 years
|
|
gptkbp:provides_information_on
|
ACC/ AHA guidelines
NCEPATPIII
|
|
gptkbp:safety_features
|
Category C
|
|
gptkbp:side_effect
|
fatigue
muscle pain
abdominal pain
allergic reactions
diarrhea
gallstones
pancreatitis
elevated liver enzymes
|
|
gptkbp:type_of
|
163222-33-1
|